FBnTP Imaging of Breast Cancer

Summary

Our preclinical studies suggest the capacity of the positron emission tomography imaging agent 18F-fluorobenzyl triphenyl phosphonium (FBnTP) to detects early-stage small breast tumors (e.g., DCIS), and differentiates benign from malignant masses with better accuracy than that obtained by existing breast imaging tools.

Timeline

Start

2015-03-12

Primary completion

2021-12-13

Completion

2021-12-13

Outcome

Outcome not reported

Stopped (Business): “Lock of funding”

Drugs

Indications